Charts

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. The post 3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Amicus Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. The post 3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. The post 7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Friday,AbbVie Inc(NYSE:ABBV) reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating theconsensus of ...

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

William Blairhas upgradedAbbVie Inc(NYSE:ABBV), noting confidence in the company’s growth outlook over the near ...

Investors in ImmunoGen, Inc. (IMGN) saw new options become available today, for the August 16th expiration..

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Dividend Aristocrats are a strong group of stocks overall with better choices available and worse choices as well. The post 7 Dividend Aristocrats That Will Pay You for Years to Come appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

Ultragenyx Pharm sees its Relative Strength Rating enter the 80-plus level.

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. ...

The company is grappling with losing Humira's patent protection in 2023.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. The post 3 Biotech Stocks Set for Breakthroughs in 2024 appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion ...

The acquisition fills an immediate need with some extras to boot.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. The post 3 Stocks at the Forefront of Medical Innovation appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

A Relative Strength Rating upgrade for Tarsus Pharmaceuticals shows improving technical performance.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks of a lot of well-known and historically great companies are on sale right now. Many marquee names haven't shared in this year's market rally and are in the red for 2023. This presents a fantastic opportunity for investors to buy great stocks at distressed prices. The post The 7 Most Undervalued Growth Stocks to Buy in December appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component ImmunoGen, Inc. (IMGN) was identified as having a larger market cap than the smaller end of the S&P 500, for example Tapestry Inc (TPR), according to The Online Investor..

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

Symbols mentioned in this story: XBI, IMGN, MRTX, APLS Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

It's making a major acquisition to beef up a key area of its pipeline.

SystImmuneandBristol Myers Squibb & Co(NYSE: BMY)announcedan exclusive license and collaboration ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. The post The 3 Best Cheap Stocks to Buy in December appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

ImmunoGen Presents Findings from Newly Diagnosed AML Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Azacitidine and Venetoclax at ASH

The big drugmaker went on a holiday shopping spree.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments. The post Market Movers: Why Big Players Are Investing Millions in These 3 Stocks appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

TG Therapeutics sees its Relative Strength Rating move into the elite 90-plus level.

Wednesday,AbbVie Inc(NYSE: ABBV) agreed to acquireCerevel Therapeutics Holdings Inc(NASDAQ: CERE) for a total ...

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks. The post Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Investors in ImmunoGen, Inc. (IMGN) saw new options begin trading this week, for the January 2026 expiration..

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologics License Application (sBLA) supporting the conversion of the accelerated approval of ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens to full approval. The application has been granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of April 5, 2024.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ImmunoGen, Inc. (NasdaqGS: IMGN) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of ImmunoGen will receive $31.26 in cash for each share of ImmunoGen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Investors in ImmunoGen, Inc. (IMGN) saw new options begin trading today, for the March 2024 expiration..

AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $10 billion. The deal, which is expected to close in ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...

Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.